Oral Consequences of Systemic Lupus Erythematosus: an Update

被引:0
|
作者
Gegout P.-Y. [1 ,2 ]
Wabbi R. [1 ,2 ]
Jung S. [1 ,2 ,3 ]
Huck O. [1 ,2 ]
机构
[1] Faculté de Chirurgie Dentaire, Université de Strasbourg, 8 Rue Sainte-Elisabeth, Strasbourg
[2] Pôle de Médecine Et Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg, Strasbourg
[3] Centre de Référence Des Maladies Rares Orales Et Dentaires (O-Rares), Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg
关键词
Autoimmune; Implant; Oral management; Orofacial manifestations; Periodontitis; Systemic lupus erythematosus;
D O I
10.1007/s40496-023-00356-x
中图分类号
学科分类号
摘要
Purpose of Review: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organs that has been associated with various oral manifestations. It affects mainly adult women, and its incidence is estimated to be 5.14 per 100,000 persons/year. Oral manifestations such as mucosal, periodontal, or carious lesions are common in SLE as well as temporomandibular joint disorders. Recent Findings: This systematic review aims to identify the oral manifestations of SLE and to evaluate the at-distance impact of SLE on oral health as well as to give clinical guidance for the oral care of SLE patients. Summary: SLE has a negative impact on general and oral health. The mechanisms underlying the development and progression of the disease are still not fully understood; however, genetic predispositions, environmental factors, or hormones might be involved in the onset of SLE. SLE treatment aims to control and limit the disease progression and expression by the adjunctive use of corticoids or immunosuppressive drugs that can impact oral health and management. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
引用
收藏
页码:184 / 195
页数:11
相关论文
共 50 条
  • [41] The complement system in systemic lupus erythematosus: an update
    Leffler, Jonatan
    Bengtsson, Anders A.
    Blom, Anna M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (09) : 1601 - 1606
  • [42] Belimumab in the management of systemic lupus erythematosus - an update
    Tesar, Vladimir
    Hruskova, Zdenka
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (07) : 901 - 908
  • [44] UPDATE ON PHARMACOTHERAPY OF SYSTEMIC LUPUS-ERYTHEMATOSUS
    REDFORD, TW
    SMALL, RE
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (23) : 2686 - 2695
  • [45] Etiopathogenesis of systemic lupus erythematosus: A 2014 update
    Mathian, A.
    Arnaud, L.
    Amoura, Z.
    [J]. REVUE DE MEDECINE INTERNE, 2014, 35 (08): : 503 - 511
  • [46] Update on systemic lupus erythematosus: autoantibodies and apoptosis
    Gordon, C
    Salmon, M
    [J]. CLINICAL MEDICINE, 2001, 1 (01) : 10 - 14
  • [47] Update on human systemic lupus erythematosus genetics
    Tsao, BP
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (05) : 513 - 521
  • [48] Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update
    Romo-Tena, Jorge
    Kaplan, Mariana J.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (06) : 562 - 571
  • [49] UPDATE ON EXPERIMENTAL SYSTEMIC LUPUS-ERYTHEMATOSUS
    MOZES, E
    WAISMAN, A
    LEVITE, M
    ZINGER, H
    REISNER, Y
    STHOEGER, Z
    [J]. ISRAEL JOURNAL OF MEDICAL SCIENCES, 1992, 28 (02): : 136 - 138
  • [50] An update on cardiovascular disorders in systemic lupus erythematosus
    Pedzich, Ewa
    Bednarek, Adrian
    Mlynarska, Julita
    Wloszek, Emilia
    Klimczak-Tomaniak, Dominika
    Gumiezna, Karolina
    Piasecki, Adam
    Rdzanek, Adam
    Sygitowicz, Grazyna
    Grabowski, Marcin
    Tomaniak, Mariusz
    [J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024,